RSS

GSAT Globalstar Inc.

Mod: DukeNukem
Last Post: 10/28/25
Followers: 6
Posts Today: 0
Views Today: 52

GSAT Stock Quote & Tools

$83.8200 ▲ +0.6000 (+0.72%) As of Oct 9, 4:00 PM EDT
Last83.8200
$ Chg0.6000
Open83.5800
High83.8500
Beta1.4496
Year High84.850
Market Cap10.86B
P/B Ratio36.85
EPS-0.51
Avg Vol (30d)580.8K
Volume636.9K
% Chg+0.72%
Prev Close83.2200
Low83.1950
VWAP83.55014
Year Low40.500
Total Shares129.56M
Shares Out129.56M
Float51.83M
ExchangeNGS
Media & Telecommunications Telecommunications

GSAT Stock Message Board Discussion

  1. Michael3290

Top 10 Most Recent News Articles

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 0

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 418

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 33

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 59

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 251

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 98

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading